In oral solid dosage form development targeting immediate release, 1,5-naphthalene disulfonic acid pharma grade (CAS 81-04-9) is deployed as an acid salt-forming agent for basic drug substances, not as a passive filler. The acid addition is fixed at 0.50 mol of 1,5-naphthalene disulfonic acid per mole of monoamine free base; for a free base molecular weight of 300–500 g/mol, this yields a neutral 2:1 (base:acid) salt whose counterion fraction ranges from 22–39 wt%. Over-acidification beyond 0.55 mol per mole of base produces a mixed 1:1 hydrogen salt, which increases hygroscopicity and shifts dissolution pH dependence. Salt formation is performed in a jacketed glass-lined reactor at 20–25°C using 95% ethanol or 90% isopropanol, with the free base added to the acid solution to avoid basic hydrolysis. After crystallization, the slurry is filtered through a pressure filter at 0.5 MPa differential, washed with cold solvent, and dried in a vacuum tray dryer at 40°C until residual solvent is 0.5% w/w. The milled salt is then wet-granulated in a high-shear granulator with impeller speed 300 rpm and chopper speed 1500 rpm; purified water is added at 1.5–2.0 kg/min to a final granule moisture of 18–20% w/w. Drying in a fluid-bed dryer with inlet air at 60–65°C reduces loss on drying to 1.5–2.0% w/w. Compression on a rotary tablet press at 12–25 kN yields tablets of 6–10 mm diameter with hardness 60–100 N and friability below 1.0% w/w. Compliance requires USP 905 for content uniformity, USP 711 apparatus II at 50 rpm in 0.1 N HCl for dissolution, USP 1216 for tablet friability, and ICH Q3D for elemental impurities. Terminal products are immediate-release oral tablets of basic amines, typically 100–500 mg total core weight. Processing at relative humidity above 60% requires pre-drying of the salt, because residual free sulfonic acid increases particle cohesion and causes sticking during compression.

What Capsule Fill Weight Limit Arises When the 2:1 Salt of 1,5-NDSA Has Bulk Density Below 0.4 g/mL?

The fill weight ceiling for hard gelatin or HPMC capsules is governed by bulk density, tap density, and the compression ratio of the naphthalene-1,5-disulfonate salt. After spray drying or vacuum drying, the 2:1 salt is passed through a cone mill equipped with a 0.6 mm screen at 1200 rpm; bulk density can fall to 0.32–0.38 g/mL and tap density to 0.48–0.55 g/mL. Under these conditions, a size 0 capsule filled with a single tamping pin on an intermittent-motion encapsulator reaches only 350–450 mg of pure salt, while a two-stage tamping station with 3.0 mm penetration depth increases the fill to 500–550 mg. The formulation addition ratio remains 0.50 mol of 1,5-NDSA per mole of monoamine free base, but the final capsule blend dilutes the salt to 10–30 wt% with microcrystalline cellulose 40–60 wt% and croscarmellose sodium 2–4 wt%. Filling is performed at 25°C and 35–40% relative humidity; at RH above 55%, the salt absorbs surface moisture and fill weight RSD deteriorates to 3.5–5.0%, exceeding the 2.0% RSD control limit. Two-piece HPMC capsules exhibit lower shell-to-powder friction than gelatin, requiring reduced dosator compression force to avoid shell splitting at values above 80 N. Compliance is governed by USP 711 dissolution, USP 905 uniformity of dosage units, ICH Q3D elemental impurities, and FDA 21 CFR Part 211 for finished pharmaceuticals. Terminal product types are immediate-release hard capsules containing basic amine APIs as 1,5-NDSA salts, including size 0 and size 1 two-piece hard capsules. The operational boundary is set by electrostatic charge: if the salt is milled at low humidity below 25% RH, static charging reduces flowability and compacts in the powder plug, requiring addition of 0.5–1.0% w/w colloidal silicon dioxide.

Granules intended for reconstitution can be produced as the 1:1 hydrogen salt of 1,5-NDSA when the formulation target is reduced aqueous solubility and taste-masking of a basic active. In this stoichiometry, 1.00 mol of 1,5-naphthalene disulfonic acid is added per mole of monoamine free base; for a free base with molecular weight 350 g/mol, the salt contains 45.2 wt% counterion and leaves one sulfonic acid group protonated. The resulting salt exhibits pH-dependent dissolution, with slow dissolution in artificial saliva at pH 6.8 and faster release in 0.1 N HCl, a profile suited to granules for oral suspension in pediatric or geriatric use. The granulation formula comprises the salt at 15–25 wt%, lactose monohydrate 50–60 wt%, mannitol 10–15 wt%, sodium citrate 0.3–0.5 wt%, xanthan gum 0.2–0.3 wt%, and a flavor system below 0.5 wt%. Granulation is performed in a top-spray fluid-bed granulator on a 2.0 kg batch; binder solution is purified water with 5% w/w povidone K30, sprayed at 8–12 g/min with atomizing air pressure 2.0–2.5 bar and inlet air temperature 55–60°C. Drying continues until loss on drying is 2.0–2.5% w/w. The dried granules are sieved through 0.8 mm and filled into sachets at 500–1000 mg fill weight. After reconstitution, sodium citrate maintains suspension pH at 5.0–5.5. Compliance is based on Ph.Eur. 2.9.10 water content, USP 698 flowing properties, USP 711 dissolution, and ICH Q3D elemental impurities. Terminal product types are single-dose sachets of granules for oral suspension, reconstituted to 5 mL or 10 mL with purified water before administration. The acid salt is incompatible with carbonate or bicarbonate effervescent pairs unless neutralized, because the protonated sulfonic acid residual reacts to evolve carbon dioxide and increases sachet headspace pressure during accelerated stability testing at 40°C/75% RH.

Sterile Filtration and pH Control Boundaries for Injectable 1,5-NDSA Salts

For parenteral dosage forms, the neutral 2:1 salt is prepared from 0.50 mol of 1,5-naphthalene disulfonic acid per mole of monoamine free base and then dissolved in Water for Injection at 20–50 mg/mL as the salt. The solution pH is held at 4.5–6.5; if free acid residual exceeds 0.5% w/w, pH can drift below 4.0 on batch-to-batch comparison and cause reduced solubility of the salt. Dissolution is completed in a stainless steel vessel under nitrogen overlay to maintain dissolved oxygen below 0.1 ppm; activated carbon at 0.1% w/v is added for 15 min and removed by coarse filtration. The solution is then passed through a 0.45 μm PVDF prefilter and a 0.22 μm PVDF sterilizing-grade filter at 10–15 psi differential pressure. Terminal heat sterilization is avoided not because the sulfonate salt is thermally labile, but published data for this specific salt configuration under steam sterilization is limited, and the pH shift observed after autoclave cycles at 121°C for 15 min can exceed 0.4 pH units in low-buffer formulations. Aseptic filling into 2 mL or 5 mL Type I glass vials is performed under Grade A conditions. Compliance includes USP 790 visible particulates, USP 85 bacterial endotoxins, USP 1 injections, ICH Q3D elemental impurities, and FDA 21 CFR 211.94 drug product containers and closures. Terminal product types are injectable solutions or lyophilized powders for reconstitution. A pH below 3.5 at the injection site is an irritation risk, so sodium hydroxide solution 0.1 N may be used for adjustment, with the sodium contribution calculated for label compliance under 21 CFR 201.66 when applicable.

Modified-release pellet cores are manufactured by extrusion-spheronization when dissolution of the neutral 2:1 salt in 0.1 N HCl exceeds 120 min in USP apparatus II at 50 rpm. The salt formation addition remains 0.50 mol of 1,5-naphthalene disulfonic acid per mole of monoamine base. The pellet core formulation contains 20–35 wt% salt, microcrystalline cellulose 55–65 wt%, hypromellose 3–5 wt%, and lactose monohydrate 0–10 wt%. Purified water is added at 28–32% w/w of dry mass in a planetary mixer; the wet mass is extruded through a twin-screw extruder with L/D 25:1, screw speed 200 rpm, and a die plate of 0.8 mm × 1.0 mm. Extrudate temperature must remain below 35°C to prevent amorphous conversion of the salt, which increases dissolution rate by 20–30% and destroys the modified-release target. Spheronization at 800 rpm for 3–5 min produces pellets with diameter 0.8–1.2 mm; yield in this fraction is typically 85–92%, with fines below 0.6 mm recycled. After drying at 45°C for 2 h, pellets are coated with ethyl cellulose aqueous dispersion to 8–12 wt% weight gain using a bottom-spray fluid bed with inlet air 50°C and spray rate 4–6 g/min. Compliance standards include USP 711 apparatus III for modified release, USP 724 extended-release, and ICH Q3D elemental impurities. Terminal product types are coated pellets filled into hard capsules or sachets. If the salt is milled to particle size below 25 μm, dissolution time shortens below 60 min and the coating level must be increased beyond 15% weight gain to compensate, which is a critical scale-up failure mode on production lines using high-shear wet milling prior to extrusion.

Lyophilized Injectable Cake Architecture and Residual Moisture Boundaries

Residual moisture after lyophilization and cake appearance are the two release-defining parameters for freeze-dried injectable products containing the neutral 2:1 salt of 1,5-NDSA. The salt is prepared at 0.50 mol of 1,5-naphthalene disulfonic acid per mole of monoamine free base and dissolved at 20–40 mg/mL as salt in Water for Injection. The pre-lyophilization solution includes mannitol at 2–5 wt/v% as a crystalline bulking agent and sucrose at 0–2 wt/v% as an amorphous stabilizer; total solid content is held below 8% w/w to prevent cracking of the cake. Vials are filled to 2 mL in 10 mL Type I glass vials and partially stoppered. Freezing is conducted at -40°C shelf temperature for 120 min; primary drying at -20°C shelf temperature and chamber pressure 100–150 mTorr continues for 18–24 h. Secondary drying at 25°C for 6–8 h reduces residual moisture to 0.5–2.0% w/w as measured by USP 921. The amorphous phase glass transition is approximately -30°C; if shelf temperature is raised above -15°C before complete sublimation, collapse begins at the vial bottom and batch rejection exceeds 10% of inspected units. Compliance standards include USP 790, USP 85, ICH Q3D, and FDA 21 CFR 211.94. Terminal product types are lyophilized powders for injection reconstituted with 2 mL or 5 mL of Sterile Water for Injection. Reconstitution time must be below 60 s with gentle swirling; cakes with collapse or meltback show reconstitution times above 180 s and are rejected under USP 1 injectability requirements.